SUMMARY OF INDIRECT COMPARISON TO EVALUATE EFFICACY OF BARICITINIB WITH TARGETED SYNTHETIC AND BIOLOGIC DISEASE ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0

作者：

Emery, Paul ^{[1
]}

Dudler, Jean ^{[2
]}

Smolen, Josef ^{[3
]}

Zerbini, Cristiano ^{[4
]}

Burmester, Gerd ^{[5
]}

Fautrel, Bruno ^{[6
]}

van der Laar, Mart ^{[7
]}

Fleischmann, Roy ^{[8
]}

Fakhouri, Walid ^{[9
]}

De Leonardis, Francesco ^{[10
]}

Zhu, Baojin ^{[11
]}

Kadziola, Zbigniew ^{[12
]}

De La Torre, Inmaculada ^{[13
]}

Perrier, Clementine ^{[14
]}

Taylor, Peter C. ^{[15
]}

机构：

[1] Leeds MSK Biomed Chapel Allerton Hosp, Fac Med & Hlth, Leeds, W Yorkshire, England

[2] HFR Fribourg Hop Cantonal, Dept Rheumatol, Fribourg, Switzerland

[3] Med Univ Vienna, Dept Rheumatol, Vienna, Austria

[4] Ctr Invest Clin, Dept Rheumatol, Sao Paulo, Brazil

[5] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany

[6] Pierre & Marie Curie Univ, Dept Rheumatol, Paris, France

[7] Arthrit Ctr Twente, Dept Rheumatol, Enschede, Netherlands

[8] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA

[9] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA

[10] Eli Lilly & Co, Dept Rheumatol, Indianapolis, IN 46285 USA

[11] Eli Lilly & Co, Real World Analyt Immunol, Indianapolis, IN 46285 USA

[12] Eli Lilly & Co, Real World Analyt Capabil & Data Mart, Indianapolis, IN 46285 USA

[13] Eli Lilly & Co, Dept Med, Indianapolis, IN 46285 USA

[14] Eli Lilly & Co, Dept Med Autoimmune, Indianapolis, IN 46285 USA

[15] Univ Oxford, Botnar Res Ctr, NDORMS, Headington, England

来源：

RHEUMATOLOGY | 2019年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

074

引用

页数：2

共 50 条

[41] Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry
Kim, Ji-Won
Lee, Sun-Kyung
Jung, Ju-Yang
Suh, Chang-Hee
Shin, Kichul
Kim, Hyoun-Ah
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1819 - 1821
[42] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
Shimada, Hiromi
Kameda, Tomohiro
Kanenishi, Kenji
Miyatake, Nobuyuki
Nakashima, Shusaku
Wakiya, Risa
Kato, Mikiya
Miyagi, Taichi
Mansour, Mai Mahmoud Fahmy
Hata, Toshiyuki
Kadowaki, Norimitsu
Dobashi, Hiroaki
CLINICAL RHEUMATOLOGY, 2019, 38 (05) : 1453 - 1458
[43] Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Tawaratsumida H.
Setoguchi T.
Arishima Y.
Ohtsubo H.
Akimoto M.
Ishidou Y.
Nagano S.
Taketomi E.
Sunahara N.
Komiya S.
BMC Research Notes, 10 (1)
[44] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
Hiromi Shimada
Tomohiro Kameda
Kenji Kanenishi
Nobuyuki Miyatake
Shusaku Nakashima
Risa Wakiya
Mikiya Kato
Taichi Miyagi
Mai Mahmoud Fahmy Mansour
Toshiyuki Hata
Norimitsu Kadowaki
Hiroaki Dobashi
Clinical Rheumatology, 2019, 38 : 1453 - 1458
[45] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
Hanaoka, Hironari
Kikuchi, Jun
Hiramoto, Kazuoto
Saito, Shuntaro
Kondo, Yasushi
Kaneko, Yuko
CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
[46] Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry
Koh, J. H.
Lee, S-K
Kim, J.
Kim, H-A
Shin, K.
Min, J-K
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (02) : 269 - 278
[47] Are Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs Associated with Work Participation Improvement in Early Rheumatoid Arthritis? A Systematic Review and Meta-analysis
Marques, Mary Lucy
Alunno, Alessia
Falzon, Louise
Boonen, Annelies
Ramiro, Sofi A.
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1669 - 1671
[48] ARE BIOLOGIC AND TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ASSOCIATED WITH WORK PARTICIPATION IMPROVEMENT IN EARLY RHEUMATOID ARTHRITIS? A SYSTEMATIC REVIEW AND META-ANALYSIS
Marques, M. L.
Alunno, A.
Falzon, L.
Boonen, A.
Ramiro, S.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 522 - 523
[49] Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
Scott, I. C.
Kingsley, G. H.
Scott, D. L.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : S4 - S8
[50] Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis
Garrood, T
Scott, DL
BIODRUGS, 2001, 15 (08) : 543 - 561

← 1 2 3 4 5 →